Engitix appoints two additional international biotech industry leaders as Scientific Advisors
June 25, 2024 04:00 ET
|
Engitix Therapeutics
LONDON, June 25, 2024 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human...
Engitix Announces Appointment of Matthew Edwards Ph.D., as SVP Discovery and Emma Huang Ph.D., as VP Data Sciences
May 21, 2024 04:25 ET
|
Engitix Therapeutics
LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human...
Engitix Announces Appointment of Christopher Stevenson, Ph.D., as Chief Scientific Officer
September 05, 2023 07:00 ET
|
Engitix Therapeutics
LONDON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary...
Engitix Announces Appointment of Sonia Quaratino, M.D., Ph.D., as Independent Non-executive Director
May 09, 2023 04:00 ET
|
Engitix Therapeutics
LONDON, May 09, 2023 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human...